Associate Professor David Pattison

ATH - Associate Professor

Royal Brisbane Clinical Unit
Faculty of Medicine


  • Deputy Director & Nuclear Medicine Specialist, Department of Nuclear Medicine & Specialised PET Services, Royal Brisbane & Women’s Hospital
  • Associate Professor, School of Medicine, University of Queensland

David underwent dual specialty training in both Endocrinology and Nuclear Medicine at Royal Melbourne Hospital, Austin Hospital and Peter MacCallum Cancer Centre in Melbourne. He was appointed a staff specialist at Peter MacCallum Cancer Centre at the completion of his training, where he continued to gain experience in a quaternary referral centre for theranostics treating patients from across south-east Australia and New Zealand. In 2016 he moved to Royal Brisbane & Women’s Hospital where he is currently the Deputy Director of Department of Nuclear Medicine & Specialised PET Services and nuclear medicine lead for the RBWH radionuclide therapy service.

Research Impacts

David’s major research areas are at the intersection of his two medical specialties – Nuclear Medicine and Endocrinology – with a particular focus on theranostics for neuroendocrine tumours, thyroid cancer and prostate cancer, in addition to molecular imaging of other malignancies. He has been a chief investigator on several large competitive grants for theranostics, including redifferentiation of radioactive iodine refractory thyroid cancer (I-FIRST $2.7 million MRFF 2021), prostate cancer (UpFrontPSMA $4 million Movember/Cancer Australia 2019) and merkel cell cancer (GoTHAM $1.8 million MRFF 2018).

Over the past 5 years he has been Principal investigator of 5 prospective clinical trials, including TheraP, the first randomised controlled trial of 177LuPSMA-1007 for metastatic castrate resistant prostate cancer. Four of these are multicentre randomised controlled radionuclide therapy trials, and one is a molecular imaging trial. He has been Associate Investigator on numerous other studies, including two first-in-human trials and the first randomised crossover imaging trial of 68Ga-PSMA-11 PET/CT for staging of high-intermediate risk prostate cancer. He is a member of Australia and New Zealand Urogenital & Prostate (ANZUP) Cancer Trials Group and Melanoma And Skin Cancer (MASC) Trials Group, and sits on various national trial Management Committees.

David has a prominent national / international profile and professional involvement. Internationally, he sits on the Thyroid and Head and Neck Cancer (THANC) Foundation Medical Advisory Board for Thyroid International Recommendations Online, as the Committee lead for the section on the role of radioactive iodine in diagnostics and therapeutics. Nationally, he sits on the Australian Nuclear Science and Technology Organisation (ANSTO) Health Advisory Board and he is co-author of the Neuroendocrine Tumour Imaging section of the Clinical Oncology Society of Australia (COSA) Guidelines current revision. He is Deputy Chair of AANMS Theranostics Working Group, developing national guidelines for best practice of theranostics in Australia. He has sat on various national Medical Advisory Boards and the Herston Imaging Research Facility Research Advisory Group, and is the Chair of the Department of Nuclear Medicine & Specalised PET Services Research Committee. He is a regular reviewer for 10 national and international medical journals in nuclear medicine and endocrinology.

David has published 40 peer-reviewed papers and 1 book chapter and presented over 47 conference abstracts. A/Prof Pattison has delivered 39 invited speaker presentations in the past 5 years, in addition to numerous conference session chair contributions.

David is enthusiastic about training and mentoring of clinicians, and supervises postgraduate students (University of Queensland) in addition to nuclear medicine advanced trainees (Director of Nuclear Medicine Training at RBWH). He is passionate about medical education and was appointed to the Royal Australasian College of Physicians Committee for Joint Clinical Training (JCT) between 2015-2019, including 2 years as National Co-ordinator of Advanced Training in Nuclear Medicine. He regularly provides post-graduate teaching presentations in both Endocrinology and Nuclear Medicine and is a regular examiner for the Nuclear Medicine Oral Assessment Task. He has significant experience with mentoring and innovative introduction of new technology, including the leadership and education of a multidisciplinary team to implement an I-124 PET/CT protocol for advanced thyroid cancer, and clinical introduction of new PET tracers including 68Ga-DOTA-exendin 4 and 18F-PSMA-1007.


  • Royal Australasian College of Physicians, Royal Australasian College of Physicians
  • Masters (Coursework) of Public Health, James Cook University
  • Bachelor (Honours) of Medicine Surgery, University of Melbourne


View all Publications


View all Supervision


Featured Publications

Book Chapter

  • Pattison, David A., Miller, Julie A., Khavar, Bhadrakant and Tie, Jeanne (2018). Management of distant metastasis in differentiated thyroid cancer. Evidence-Based Endocrine Surgery. (pp. 121-140) Singapore: Springer Singapore. doi: 10.1007/978-981-10-1124-5_11

Journal Article

Conference Publication

Grants (Administered at UQ)

PhD and MPhil Supervision

Current Supervision

  • Master Philosophy — Principal Advisor

    Other advisors: